Regenerex Pharma has yet to submit quarterly reports for the periods ended March 31, 2026, and June 30, 2026, while its 2025 Annual Report was filed late. Investors face incomplete quarterly financial information until those reports are filed, although Regenerex says it expects no change to operations or Business strategy.

Key Highlights

  • Regenerex acknowledges it did not submit Notifications of Late Filing on Form 12b for the outstanding quarterly reports.
  • Management says additional review procedures are being used to reconcile financial records and strengthen reporting processes.
  • Quarterly reports for the periods ended March 31, 2026, and June 30, 2026, remain outstanding.
  • Regenerex is completing accounting, reconciliation, financial reporting and review work for the delayed reports.

Regenerex Pharma, Inc. still has not submitted quarterly reports for the periods ended March 31, 2026, and June 30, 2026. The outstanding reports leave financial information for those periods incomplete, while the company says its operations and business strategy are not expected to change.

March 31 and June 30 Reports Remain Outstanding

Regenerex is completing accounting, reconciliation, financial reporting and review work for the quarterly statements and related disclosures. Regenerex also acknowledges that it did not submit Notifications of Late Filing on Form 12b for the outstanding quarterly reports. Management, accounting and financial reporting personnel, along with professional advisers, are working to complete the reports and restore current periodic reporting status as soon as practicable.

Incomplete Quarterly Data, Operations Continue

Regenerex has added procedures to review and reconcile financial information and supporting records before completing the outstanding reports. The company says those steps are intended to establish a reliable basis for ongoing periodic reporting. Regenerex intends to submit the reports as soon as practicable and provide further information through its SEC reports as appropriate. Until submission, shareholders and other interested parties are cautioned to treat the quarterly financial information as incomplete and evaluate it alongside the company’s other SEC filings. The company says it continues to operate in the ordinary course and currently anticipates no change to its operations, business strategy or ongoing business activities.